Netildex (Netilmicin Sulfate, Dexamethasone Disodium Phosphate)

Netildex is indicated for ophthalmic conditions where bacterial infection and inflammation coexist.

• Bacterial conjunctivitis: lowers bacterial count and relieves redness, discharge, and discomfort.
• Bacterial keratitis: eradicates pathogenic organisms and promotes corneal healing.
• Post‑operative ocular inflammation: suppresses inflammatory response after eye surgery while preventing infection.

• Netilmicin binds to the bacterial 30S ribosomal subunit, blocking protein synthesis and leading to bacterial cell death. Dexamethasone activates intracellular glucocorticoid receptors, inhibiting phospholipase A2 and reducing the release of prostaglandins and cytokines, thereby diminishing ocular inflammation.

Adverse reactions may occur with any ophthalmic preparation. Most are mild and transient.

Common Side Effects

• Stinging or burning sensation on instillation.
• Transient blurred vision.
• Mild ocular irritation or itching.
• Increased tearing.
• Conjunctival hyperemia.
• Temporary feeling of foreign body.

Serious or Rare Side Effects

• Allergic contact dermatitis or severe hypersensitivity.
• Corneal ulceration or secondary infection.
• Significant rise in intra‑ocular pressure.
• Cataract formation with prolonged use.
• Systemic aminoglycoside toxicity (nephro‑ or ototoxicity) in rare cases.
• Vision loss if untreated infection progresses.

Before using Netildex, consider the following safety measures.

• Hypersensitivity assessment: avoid if known allergy to aminoglycosides or corticosteroids.
• Supervision: use only under ophthalmic professional guidance.
• Contact lens use: discontinue lenses during treatment to prevent drug absorption.
• Intra‑ocular pressure monitoring: regular checks recommended for prolonged therapy.
• Avoid in viral or fungal eye infections unless specifically directed.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Netildex may interact with other ocular or systemic agents.

Major Interactions (Avoid)

• Systemic aminoglycosides: increased risk of nephro‑ and ototoxicity.
• Concurrent topical corticosteroids: additive intra‑ocular pressure elevation.
• Non‑steroidal anti‑inflammatory eye drops: may diminish steroid efficacy.

Moderate Interactions (Monitor Closely)

• Systemic corticosteroids: potential for systemic glucocorticoid effects.
• Anticholinergic ophthalmic agents: possible alteration of pupil dynamics.
• Antiviral eye medications: monitor for reduced antiviral activity.